Please login to the form below

Not currently logged in
Email:
Password:

Apellis

This page shows the latest Apellis news and features for those working in and with pharma, biotech and healthcare.

FDA approves Apellis’ Empaveli for rare blood disease

FDA approves Apellis’ Empaveli for rare blood disease

Whereas Alexion’s Soliris and its follow-up therapy Ultomiris target the C5 pathway, Apellis’ drug targets the compliment protein C3 – the central protein in the complement cascade. ... Apellis is also conducting a study of Empaveli in

Latest news

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Dr Robert Kim joins Apellis as chief medical officer Dr Robert Kim joins Apellis as chief medical officer

    Brings experience from Novartis, Genentech and GSK. Dr Robert Kim has taken up a role at Apellis Pharmaceuticals as chief medical officer, bringing to the US clinical stage immunotherapy company experience ... In his new role at Louisville,

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...